封生命健康股份有限公司2023年度非经营性资金占用及其他关联资金往来情况汇总表 单位:人民币万元 | 非经营性资金占用 | | 占用方与上市公司 | 上市公司核算 | 2023年期初占用 | 2023年度占用累计 | 2023年度占用资 | 2023年度偿还累 | 2023年期末占 | | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 14 | 资金占用方名称 --- | 的关联关系 | 的会计科目 | 资金余额 | 发生金额(不含利息) 金的利息(如有) | | 计发生金额 | 用资金余额 | 占用形成原因 | | | 控股股东、实际控制~ | 111 | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际控 | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 其他 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥11.59 billion, a decrease of 12.38% compared to ¥13.23 billion in 2022[36]. - The net profit attributable to shareholders for 2023 was approximately ¥302.12 million, down 30.30% from ¥433.28 million in 2022[36]. - The net profit after deducting non-recurring gains and losses for 2023 was approximately ¥243.07 million, a decline of 40.55% from ¥408.65 million in 2022[36]. - The net cash flow from operating activities for 2023 was approximately ¥1.59 billion, a decrease of 33.99% compared to ¥2.41 billion in 2022[36]. - The total assets at the end of 2023 were approximately ¥30.73 billion, an increase of 2.32% from ¥30.02 billion at the end of 2022[37]. - The net assets attributable to shareholders at the end of 2023 were approximately ¥10.10 billion, a decrease of 0.85% from ¥10.19 billion at the end of 2022[37]. - The basic earnings per share for 2023 were ¥0.1526, down 30.29% from ¥0.2188 in 2022[36]. - The weighted average return on net assets for 2023 was 2.99%, a decrease of 1.26% from 4.25% in 2022[36]. - The company reported a net profit of ¥177.14 million in Q1 2023, with a significant drop to -¥202.80 million in Q4 2023[41]. - The company achieved a total operating revenue of 1,159,459.04 million yuan, a decrease of 163,777.52 million yuan, representing a year-on-year decline of 12.38%[56]. - The operating profit was 92,651.12 million yuan, down by 71,848.85 million yuan, reflecting a year-on-year decrease of 43.68%[56]. - The net profit attributable to shareholders was 30,212.20 million yuan, a reduction of 13,136.15 million yuan, which is a year-on-year decline of 30.30%[56]. Revenue Growth in Medical Business - In 2023, the company achieved significant revenue growth in its medical business, with Beijing Huasheng Rehabilitation Hospital's income increasing substantially after obtaining Beijing's medical insurance qualification, and bed utilization rates continuing to rise[2]. - Chongqing Songshan Hospital's medical revenue grew by over 40% in 2023, with bed utilization rates at a healthy level, driven by optimized discipline layout and talent introduction[8]. - Beijing Huasheng Rehabilitation Hospital reported a rapid increase in operating income and a bed utilization rate exceeding 80% in 2023, with 300 beds open across 16 departments[9]. - The company will continue to innovate its medical service business model, focusing on the "big health" industry[7]. - The company is implementing a three-step development strategy for its hospitals, focusing on building high-quality medical teams and enhancing service quality[135]. - The company plans to develop a modern health service system at Chongqing Songshan Hospital while improving service quality and brand image[135]. Product Development and Innovation - The company launched 14 new functional skincare products, including three types of azelaic acid acne creams, further enriching its "big skin" product matrix[4]. - The company has expanded its product offerings, including the approval of Moxifloxacin Sodium Chloride Injection, enhancing its portfolio in dermatology, tuberculosis, and oncology, contributing to new revenue growth points[60]. - The company has launched several new products in the dermatology segment, including the Tri-Retinoic Acid Acne Gel and Tri-Retinoic Acid Clear Gel, leveraging its 30 years of clinical experience in dermatology[60]. - The company is focusing on expanding its OTC market presence and enhancing its overseas raw material drug market efforts[54]. - The company is focusing on developing high-value-added raw materials and key intermediates through collaboration with domestic and international research institutions[132]. - The company intends to expand its product range to include functional skincare products, transitioning from disease treatment to disease prevention and daily care[132]. Research and Development - The company emphasizes the importance of internal collaboration and has established Huabong Pharmaceutical Research Institute to enhance its R&D capabilities[2]. - The company has a strong R&D team focused on technological innovation, which supports product quality and profitability[71]. - Research and development expenses increased by 8.80% year-on-year, totaling ¥419,138,741.86 in 2023[108]. - The number of R&D personnel rose by 5.31% to 1,349, with a notable increase in master's degree holders by 34.06%[112]. - The company has developed 2 first-class new drugs and over 20 generic drugs, with more than 180 patents granted, showcasing strong R&D capabilities[84]. - The company is focusing on improving product competitiveness through innovative process verification stages[110]. Market Expansion and Strategic Partnerships - The company has established long-term partnerships with international pharmaceutical companies such as Abbott, Johnson & Johnson, Eli Lilly, and Merck, focusing on the export of active pharmaceutical ingredients to developed countries like Europe, America, and Japan[58]. - The company has covered over 200,000 retail endpoints, actively expanding its marketing channels in response to national healthcare reforms, including partnerships with over 10 online platforms such as Alibaba Health and Meituan[61]. - The company is actively developing high-end and specialty raw materials at its Changshou and Hanchong International raw material production bases, which have recently commenced operations[60]. - The company is enhancing its digital transformation across production bases, aiming for high efficiency, quality, and eco-friendliness in its operations[60]. - The company is focusing on expanding its OTC market presence and enhancing its overseas raw material drug market efforts[54]. - The company aims to expand sales and market presence by enhancing global market network and increasing customer base[139]. Tourism Business Performance - The company’s tourism segment saw a significant recovery, with Lijiang Co. achieving record-high operating revenue due to increased visitor numbers[55]. - The domestic tourism market in 2023 experienced a rapid recovery after three years of decline, with inbound and outbound tourism markets achieving expected growth[146]. - The company aims to enhance its tourism business by developing a scenic transportation system and mid-to-high-end accommodation, leveraging resources from its platforms, Huabang Yikang and Lijiang Co.[147]. - The tourism performance is supported by famous 5A scenic spots in provinces like Yunnan and Guangxi, enhancing visitor experiences[72]. - Increased competition in the tourism market, particularly from international hotel brands, is a concern; the company plans to improve hotel quality and control operating costs to enhance revenue[148]. Governance and Compliance - The company maintains a governance structure that complies with regulations, ensuring transparency and protecting the rights of all shareholders, especially minority investors[152]. - The board of directors consists of six members, including two independent directors, ensuring compliance with legal requirements and promoting effective decision-making[153]. - The company has established specialized committees within the board to provide scientific and professional opinions, enhancing the decision-making process[153]. - The company has a complete and independent business system, capable of independently formulating product marketing strategies without reliance on shareholders[161]. - The company has established a robust internal control environment with clear responsibilities and checks and balances[191]. - The internal control audit report indicated that the company maintained effective financial reporting internal controls as of December 31, 2023[196]. Environmental and Safety Measures - The company has increased its investment in environmental protection and safety measures, ensuring a stable operational environment[68]. - The company has complied with all relevant environmental protection laws and regulations during its operations[199]. - The company obtained an environmental management system certification in accordance with GB/T24001-2016/ISO14001:2015 standards[200]. - The company has implemented strict controls on wastewater, waste gas, solid waste, and noise emissions to meet regulatory standards[199]. - The company is focusing on green production technologies to reduce waste generation and improve economic efficiency[76]. - Safety production risks are present due to the handling of hazardous chemicals, necessitating strict adherence to safety regulations[140]. Challenges and Risks - The company faces risks related to raw material price fluctuations, which significantly impact business costs and gross margins[144]. - Environmental protection risks arise from increasing regulatory scrutiny, potentially leading to higher operational costs[140]. - The company has established a risk-sharing mechanism with clients to mitigate foreign exchange risks associated with international sales[141]. - The company has implemented measures to mitigate risks from natural disasters and pandemics, including research and preventive strategies to enhance resilience[148]. - The company has undergone changes in its main business operations, expanding into healthcare services and new materials since 2015[35]. Shareholder Engagement and Remuneration - The company distributed a cash dividend of RMB 2.20 per 10 shares, totaling RMB 434,810,944.26, which represents 100% of the profit distribution amount[186]. - The total distributable profit for the period was RMB 1,053,716,228.03, indicating a strong profitability[188]. - The total remuneration for directors, supervisors, and senior management in 2023 amounted to 8.7475 million yuan, linked to their positions and performance[173]. - The annual shareholders meeting had an investor participation rate of 26.97% on May 17, 2023, and the first extraordinary shareholders meeting had a participation rate of 28.52% on December 20, 2023[162]. - The company has not implemented any stock incentive plans or employee stock ownership plans during the reporting period[190].

证券代码：002004 证券简称：华邦健康 公告编号：2024011 华邦生命健康股份有限公司 第八届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开及议案审议情况 华邦生命健康股份有限公司（以下简称"公司"）第八届董事会第十八次会 议通知于 2024 年 4 月 15 日以电子邮件的形式发出，2024 年 4 月 25 日通过现场 +视频会议的方式召开，公司 6 名董事都参加了本次会议，会议的通知及召开符 合《公司法》及《公司章程》的规定，合法有效。会议由董事长张松山先生主持， 经与会各位董事认真讨论研究，审议通过了以下议案： 本议案尚需提交至公司 2023 年年度股东大会审议。 （三）会议以 6 票赞成、0 票反对、0 票弃权的表决结果审议通过了《2023 1 年度财务决算报告》； （一）会议以 6 票赞成、0 票反对、0 票弃权的表决结果审议通过了《2023 年度总经理工作报告》； （二）会议以 6 票赞成、0 票反对、0 票弃权的表决结果审议通过了《2023 年度董事会工作报告》； 详见公司于同日在巨潮资讯网（w ...

| 四川华信(集团)会计师事务所 | 地址:成都市洗面桥街 18 号金茂礼都南 28 楼 | | --- | --- | | | 电话:(028) 85560449 | | (特殊普通合伙) | 传真:(028) 85560449 | | | 邮编:610041 | | SI CHUAN HUA XIN (GROUP) CPA (LLP) | 电邮: schxzhb@hxcpa.com.cn | 华邦生命健康股份有限公司 2023 年度审计报告 川华信审(2024)第 0030 号 目录: 1、审计报告 2、合并及母公司资产负债表 3、合并及母公司利润表 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn 4、合并及母公司现金流量表 5、合并及母公司所有者权益变动表 6、财务报表附注 华邦牛命健康股份有限公司 审计报告 审计报告 川华信审(2024)第 0030 号 华邦生命健康股份有限公司全体股东: 一、审计意见 我们审计了华邦生命健康股份有限公司(以下简称"华邦生命健康"或"贵公司"财务 报表,包括 2023年12月 31日的合并及母公司资产负债表,202 ...

证券代码：002004 证券简称：华邦健康 公告编号：2024015 华邦生命健康股份有限公司 关于续聘2024年度审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开 了第八届董事会第十八次会议、第八届监事会第十一次会议，审议通过了《关于 续聘 2024 年度审计机构的议案》，拟续聘四川华信（集团）会计师事务所（特殊 普通合伙）（以下简称"四川华信"）为公司 2024 年度审计机构，本事项尚需提 交公司 2023 年度股东大会审议。 一、拟续聘 2024 年度审计机构事项的情况说明 四川华信具有证券期货相关业务从业资格，具备多年为上市公司提供优质审 计服务的丰富经验和强大的专业服务能力，能够较好满足公司建立健全内部控制 以及财务审计工作的要求。 四川华信自担任本公司年度报告的审计机构以来，于审计期间坚持独立、客 观、公正的审计准则，恪守职业道德，较好地完成了与公司约定的各项审计业务。 公司对其工作能力、职业素养等各方面均表示满意。在 2023 年度的审计工作中， 四 ...

2023 年度监事会工作报告 一、监事会会议召开情况 报告期内，公司监事会共召开了 3 次会议，会议主要情况如下: 1、第八届监事会第八次会议于 2023 年 4 月 25 日召开，会议审议通过了以 下事项： （1）《2022 年度监事会工作报告》； （2）《2022 年度财务决算报告》； （3）《2022 年度利润分配预案》； （4）《<2022 年年度报告>及其摘要》； （5）《关于对 2022 年年度报告的审核意见的议案》； （6）《2023 年第一季度报告》； （7）《关于对 2023 年第一季度报告的审核意见的议案》； （8）《2022 年度公司内部控制自我评价报告》； （9）《关于计提商誉减值准备的议案》； 2、第八届监事会第九次会议于 2023 年 8 月 25 日召开，会议审议通过了以 下事项: （1）《2023 年半年度报告及摘要》； （2）《关于对 2023 年半年度报告的审核意见的议案》。 3、第八届监事会第十次会议于 2023 年 10 月 27 日召开，会议审议通过了以 下事项： （1）《2023 年第三季度报告》； （2）《关于对 2023 年第三季度报告的审核意见的议案》。 二、 ...

| 四川华信(集团)会计师事务所 | 地址:成都市洗面桥街 18 号金茂礼都南 28 楼 | | --- | --- | | 电话:(028) 85560449 | | | (特殊普通合伙) | 传真:(028) 85560449 | | 邮编:610041 | | | SI CHUAN HUA XIN (GROUP) CPA (LLP) 电邮: schxzhb@hxcpa.com.cn | | 华邦生命健康股份有限公司 2023 年度内部控制审计报告 川华信专(2024)第 0429 号 目录: 1. 报告正文 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ace.mof.gov.cn） 华邦生命健康股份有限公司 内部控制审计报告 内部控制审计报告 川华信专(2024) 第 0429 号 华邦生命健康股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了华 邦牛命健康股份有限公司(以下简称"华邦生命健康"或"贵公司")2023年12月31日的财 务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控 ...

证券代码：002004 证券简称：华邦健康 公告编号：2024013 华邦生命健康股份有限公司 关于计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《企业会计准则》《深圳证券交易所股票上市规则》相关规定的要求， 为了真实、准确地反映公司截止 2023 年 12 月 31 日的资产状况和财务状况，公 司基于谨慎性原则，对各类资产进行了充分的分析、测试和评估，对可能发生的 各项减值损失计提减值准备。 （二）本期计提资产减值准备的资产范围和金额 2023 年度，公司计提各项准备合计 38,243.83 万元，具体如下： | 项目 | 计提金额（万元） | | | --- | --- | --- | | 信用减值损失 | | 234.72 | | 存货跌价损失 | | 9,149.63 | | 合同资产减值损失 | | 7.51 | | 商誉减值损失 | | 20,816.11 | | 长期资产减值损失 | | 8,035.86 | | 合计 | | 38,243.83 | 华邦生命健康股份有限公司（以下简称"公司"）于 2024 年 4 ...

华邦生命健康股份有限公司 关于召开 2023 年度业绩网上说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002004 证券简称：华邦健康 公告编号：2024019 （问题征集专题页面二维码） 华邦生命健康股份有限公司 董 事 会 2024 年 4 月 27 日 1 华邦生命健康股份有限公司（以下简称"公司"）已于 2024 年 4 月 27 日在 公司指定信息披露网站巨潮资讯网（www.cninfo.com.cn）披露了公司《2023 年年 度报告》及其摘要。为使广大投资者进一步了解公司经营情况，公司拟于 2024 年 4 月 29 日（星期一）下午 15:00-17:00 在全景网举行 2023 年度业绩说明会， 本次说明会将采用网络远程方式举行，投资者可登陆"全景•路演天下" （http://rs.p5w.net）参与本次年度业绩说明会。出席本次年度业绩说明会的人员 有：公司董事、总经理张海安先生，董事、董事会秘书彭云辉女士，独立董事刘 忠海先生，财务总监王剑先生。 为充分尊重投资者、提升交流的针对性，现就公司 2023 年度业绩 ...

本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开及议案审议情况 证券代码：002004 证券简称：华邦健康 公告编号：2024012 华邦生命健康股份有限公司 第八届监事会第十一次会议决议公告 华邦生命健康股份有限公司（以下简称"公司"）第八届监事会第十一次会 议通知于 2024 年 4 月 15 日以电子邮件的形式发出，2024 年 4 月 25 日通过现场 会议的方式召开，公司 3 名监事都参加了本次会议，会议的通知及召开符合《公 司法》及《公司章程》的规定，合法有效。会议由监事会主席王政军先生主持， 经与会各位监事认真讨论研究，审议通过了以下议案： （一）会议以 3 票赞成、0 票反对、0 票弃权的表决结果审议通过了《2023 年度监事会工作报告》； 详见公司于同日刊登在巨潮资讯网（www.cninfo.com.cn）的《2023 年度监 事会工作报告》。 本议案尚需提交至公司 2023 年年度股东大会审议。 （二）会议以 3 票赞成、0 票反对、0 票弃权的表决结果审议通过了《2023 年度财务决算报告》； 详见公司于同日在巨潮资讯网（ww ...